Relmada Therapeutics (RLMD) Tops Q3 EPS by 18c

Relmada Therapeutics (NASDAQ: RLMD) reported Q3 EPS of ($0.73), $0.18 better than the analyst estimate of ($0.91).

For earnings history and earnings-related data on Relmada Therapeutics (RLMD) click here.

You May Also Be Interested In

• Etsy upgraded to buy at BofA on durable growth, buyback potential
• UBS Reiterates Buy Rating on Dutch Bros Inc. (BROS): 'One of Strongest Growth Stories in Restaurants'
• Walmart (WMT) Tops Q2 EPS by 7c, Beats on Revenue; Offers FY27 EPS Guidance